Skip to main content

Psoriasis clinical trials at UCSF
7 in progress, 5 open to new patients

  • Anakinra for Inflammatory Pustular Skin Diseases

    open to eligible people ages 18–110

    Background: - Inflammatory pustular skin diseases are a type of autoinflammatory disease in which the immune system attacks the body s tissues. These diseases cause painful and itchy skin rashes, eye and mouth irritation, joint pain and fever. Several drugs for treating these diseases suppress the immune system. However, they can cause severe side effects when taken over a long period of time. - IL-1 is a small protein that may be important in causing the inflammation seen in pustular skin disease. Anakinra is a drug that works by blocking IL-1. It has been effective in treating some inflammatory conditions such as rheumatoid arthritis. However, anakinra has not been studied for use in patients with pustular skin disease. Researchers want to see whether anakinra will be effective in treating pustular skin disease. Objectives: - To see if anakinra can be used to treat inflammatory pustular skin disease. Eligibility: - Individuals at least 18 years of age who have inflammatory pustular skin disease. Design: - Participants will be screened with a physical exam and medical history. Their disease will be evaluated with blood tests, urine tests and imaging studies. Skin biopsies may also be collected. - Participants will have an initial visit to receive the first dose of anakinra. They will be shown how to give themselves daily injections of anakinra. - Participants will take anakinra for up to 12 weeks as long as there are no severe side effects. During this time, they will keep a study diary to record the severity of any rashes, pustules, itching, fevers, and skin or joint pain. They will bring this diary to their study visits. - Participants will have study visits at weeks 4, 8 and 12. Treatment will be monitored at these visits with blood tests, urine tests and physical exams. Depending on the effects of the treatment, participants may have the dose of anakinra increased or decreased. - Participants will have a final study visit 4 weeks after they stop taking anakinra.

    San Francisco, California and other locations

  • Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis

    open to eligible people ages 18 years and up

    The purpose of this study is to determine the best dosing strategy when using Excimer Laser to treat plaque-type psoriasis. In this study, half of the body's psoriasis will be treated with a new dosing strategy, and the other half will be treated with the conventional method. We hope to show that the new dosing strategy will result in faster improvement of psoriasis.

    San Francisco, California

  • Immunologic Response to Secukinumab in Plaque Psoriasis

    open to eligible people ages 18 years and up

    This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.

    San Francisco, California

  • Single Cell Genomics of Psoriatic Skin

    open to eligible people ages 18 years and up

    The purpose of this study is to understand how genetics play a role in psoriasis. Specifically, a genetic allele HLA-Cw6 is known to be associated with psoriasis, and this study aims to find out how it affects genetic and protein expression in patients with psoriasis, compared to healthy people, at a single-cell level using a novel flow cytometry and RNA-sequencing protocol.

    San Francisco, California

  • Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

    open to eligible people ages 6–17

    The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.

    San Francisco, California and other locations

  • A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.

    San Francisco, California and other locations

  • Chronic Plaque Psoriasis (Ps) Registry

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).

    San Francisco, California and other locations